Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Acquisitions & Divestments (2021 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of Change in Acquisitions & Divestments data on record, last reported at $47.2 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 24.36% year-over-year to $47.2 million; the TTM value through Dec 2025 reached $243.3 million, up 4.67%, while the annual FY2025 figure was $243.3 million, 4.67% up from the prior year.
  • Change in Acquisitions & Divestments reached $47.2 million in Q4 2025 per FHTX's latest filing, up from $39.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $94.5 million in Q2 2021 and bottomed at $19.0 million in Q2 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $52.7 million, with a median of $53.1 million recorded in 2022.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 79.89% in 2022, then surged 303.02% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $20.0 million in 2021, then surged by 90.5% to $38.1 million in 2022, then rose by 16.17% to $44.3 million in 2023, then skyrocketed by 41.02% to $62.4 million in 2024, then fell by 24.36% to $47.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $47.2 million in Q4 2025, $39.6 million in Q3 2025, and $76.0 million in Q2 2025.